Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure

International Heart Journal

Volumn 51, Issue 6, 2010, Pages 404-410

  Shirakabe, Akihiro ^a   Asai, Kuniya ^a   Hata, Noritake ^a   Yokoyama, Shinya ^a   Shinada, Takuro ^a   Kobayashi, Nobuaki ^a   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Acute heart failure syndrome; Cardiac remodeling; Extracellular matrix; Matrix metalloproteinases; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GELATINASE A;

ACUTE HEART FAILURE; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 78650622627     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.404     Document Type: Article

References (33)

1. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8. (Review)
2. Spinale FG. Myocardial matrix remodeling and the matrix metal-loproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-342. (Review)
3. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metallopro-teinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-96.
4. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72.
5. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumu-ra K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211-7.
6. Fukuda D, Shimada K, Tanaka A, et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocar-dial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97: 175-80.
7. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708-15.
8. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004; 6: 41-5.
9. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloprotein-ase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005; 150: 484-7.
10. Wilson EM, Gunasinghe HR, Coker ML, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002; 8: 390-8.
11. Tziakas D, Chalikias G, Parissis JT, et al. Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decom-pensated state. Interplay between their levels and metalloprotein-ase-3. Eur Cytokine Netw 2004; 15: 231-9.
12. Tziakas DN, Chalikias GK, Hatzinikolaou HI, et al. Levosi-mendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Cardiovasc Drugs Ther 2005; 19: 399-402.
13. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958-68.
14. Nieminen MS, Harjola V P. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005; 96: 5G-10G. (Review)
15. Noji Y, Shimizu M, Ino H, et al. Increased circulating matrix met-alloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J 2004; 68: 355-60.
16. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-20.
17. Coker ML, Jolly JR, Joffs C, et al. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol 2001; 281: H543-51.
18. Biolo A, Fisch M, Balog J, et al. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010; 3: 44-50.
19. Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 2001; 65: 71-5.
20. Altieri P, Brunelli C, Garibaldi S, et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 648-56.
21. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10: 328-33.
22. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
23. Wang GY, Bergman MR, Nguyen AP, et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 2006; 69: 688-96.
24. Bergman MR, Teerlink JR, Mahimkar R, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007; 292: H1847-60.
25. Yokoseki O, Yazaki Y, Suzuki J, Imamura H, Takenaka H, Isobe M. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy. Jpn Circ J 2000; 64: 352-7.
26. Brower GL, Levick S P, Janicki JS. Inhibition of matrix metallo-proteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol 2007; 292: H3057-64.
27. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metal-loproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-9.
28. Li B, Liao YH, Cheng X, Ge H, Guo H, Wang M. Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. Int J Cardiol 2006; 111: 247-55.
29. Ohtsuka T, Hamada M, Saeki H, et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 2003; 91: 1024-7, A8.
30. Nakaya R, Uzui H, Shimizu H, et al. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 2005; 105: 67-73.
31. Yasuda S, Miyazaki S, Kinoshita H, et al. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin Sci (Lond) 2007; 112: 43-9.
32. Tziakas DN, Chalikias GK, Parissis JT, et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004; 94: 269-77.
33. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metallo-proteinases. Circ Res 2002; 91: 1127-34.